Biomarker · Gene alteration

KIT mutation

Activating KIT mutations (exon 9, 11, 13, 17 and others) detected by sequencing of tumor tissue or marrow; used as a predictive marker for KIT inhibitors in gastrointestinal stromal tumor and as a diagnostic marker in systemic mastocytosis.

CI-BIO-00000050KIT graph →NCIt C39712

Also calledc-KIT mutation · KIT exon 11 · KIT D816V · CD117

Derived

Associated cancers (15)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Gastrointestinal Stromal Tumor	69	64	4	1	2 / 19 / 23 / 25 / 0
Malignant Neoplasm	15	15	—	—	0 / 0 / 0 / 15 / 0
Melanoma	9	9	—	—	0 / 2 / 4 / 3 / 0
Acute Myeloid Leukemia	4	3	1	—	0 / 2 / 0 / 2 / 0
Systemic Mastocytosis

Derived

Drugs with predictive evidence (14)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
ImatinibSmall Molecule	61	37	24	A	31 / 21	Anal Melanoma, Chronic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Gastrointestinal Stromal Tumor +7
SunitinibSmall Molecule	30	15

Curated evidence

Predictive evidence items (105)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 51–100 of 105 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KIT V560_L576del1
Regorafenib Anhydrous

Regulatory

Approvals mentioning the linked drugs (253)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpd

Clinical trials

Active trials (63)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 35 recruiting · 11 active phase 3 · 501 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–50 of 63 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	Phase 2

Literature

Linked publications (44)

Publications linked to the scope gene(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–25 of 44 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
· J Clin Oncol · 2003 · PMID 14645423 · validated civic_curation pubmed
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
· Eur J Cancer · 2006 · PMID 16624552 · validated civic_curation pubmed
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
· J Clin Oncol · 2006 · PMID 16954519 · validated civic_curation pubmed
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.
· Blood · 2006 · PMID 16384925 · validated

KIT N822K + KIT W557_K558del2
Regorafenib Anhydrous	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	3	accepted	EID4169 In a set of preclinical experiments associated with gastrointestinal stromal tumor, the effects of the tyrosine kinase inhibitor regorafenib on Ba/F3 cell lines harboring the primary regorafenib-sensi… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
Imatinib + SunitinibSubstitutes	Gastrointestinal Stromal Tumor	Predictive	D	Supports Resistance	4	accepted	EID7414 Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with primary TKI-sensitizing del 557-558 mutation, which induced IL-3 independent growth… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic

KIT Exon 9 Mutation2
Sunitinib	Gastrointestinal Stromal Tumor	Predictive	B	Supports Sensitivity Response	3	accepted	EID1223 Primary tumor genotyping of 89 patients with metastatic GIST given 2nd-line sunitinib treatment after prior imatinib therapy failure, revealed an improved response to sunitinib in patients with KIT ex… (full text at CIViC) PMID 22439647 · Rutkowski et al., 2012 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	B	Supports Sensitivity Response	3	accepted	EID1424 In a study of 78 patients with gastrointestinal stromal tumors treated with sunitinib, patients with Kit exon 9 mutations or wildtype (lacking KIT or PDGFRA mutations) showed increased progression fre… (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic

KIT W557_K558del3
Sunitinib	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	3	accepted	EID4082 Patients 11, 69, and 73 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT… (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic
Regorafenib + SunitinibSubstitutes	Gastrointestinal Stromal Tumor	Predictive	D	Supports Sensitivity Response	2	accepted	EID4087 In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to sunitinib (IC50: 7 +/- 2nmol/L) and regorafenib (IC50: 30 … (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
Imatinib	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	2	accepted	EID2481 In an in vitro study of imatinib sensitivity, KIT W557_K558del was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the … (full text at CIViC) PMID 14645423 · Heinrich et al., 2003 · Open in CIViC	civic

KIT V560D3
Sunitinib	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	3	accepted	EID4122 Patient 72 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V560D mutati… (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic
Imatinib Mesylate	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID5348 In an in vitro study, Chinese hamster ovary cells expressing KIT V560D mutation demonstrated sensitivity to imatinib treatment (IC50 = 100 vs IC50 = 1000) when compared to Chinese hamster ovary cells … (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic
Sunitinib	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	2	accepted	EID4077 In an in vitro study, Chinese hamster ovary cells expressing KIT V560D demonstrated comparable sensitivity to sunitinib treatment compared to cells expressing ligand activated wild-type KIT (IC50<100 … (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic

KIT L576P5
Sunitinib	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	2	accepted	EID4136 Patient 29 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT L576P mutati… (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic
Dasatinib + Imatinib + NilotinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID303 Ba/F3 cells harboring the KIT L576P mutation are sensitive to nilotinib, imatinib and lower concentrations of dasatinib. PMID 17372901 · Antonescu et al., 2007 · Open in CIViC	civic
Dasatinib + ImatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID4141 In an in vitro study, COS-7 cells expressing KIT L576P activating mutation demonstrated sensitivity to imatinib and dasatinib treatments. Sensitivity was determined by assessing reduced mutant KIT aut… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC	civic
Dasatinib	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID42 The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding… (full text at CIViC) PMID 19671763 · Woodman et al., 2009 · Open in CIViC	civic
Imatinib + Nilotinib + SorafenibSubstitutes	Melanoma	Predictive	D	Supports Resistance	3	accepted	EID34 The melanoma cell line WM3211 (derived from an acral lentiginous melanoma), which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L… (full text at CIViC) PMID 19671763 · Woodman et al., 2009 · Open in CIViC	civic

KIT EXPRESSION3
Sunitinib	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID10180 Phase II trial of sunitinib in 40 patients with first recurrence of primary glioblastoma. Median PFS 2.2 mo, median OS 9.2 mo, 5 stable disease >=6 months, no objective responses, so primary study end… (full text at CIViC) PMID 24311637 · Hutterer et al., 2014 · Open in CIViC	civic
Imatinib	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID1024 Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT). PMID 18607592 · Kalender et al., 2009 · Open in CIViC	civic
〃	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID1025 Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment… (full text at CIViC) PMID 16487996 · Salvatierra et al., 2006 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Imatinib	CA Health Canada	—	Marketed in Canada as SANDOZ IMATINIB (DIN 02515547) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 25, 2023	—	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as TARO-IMATINIB (DIN 02428318) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as MYLAN-IMATINIB (DIN 02424509) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 2, 2018	—	health-canada-dpd
Imatinib	CA Health Canada	—	Marketed in Canada as MYLAN-IMATINIB (DIN 02424495) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Oct 2, 2018	—	health-canada-dpd
Midostaurin	CA Health Canada	—	Marketed in Canada as RYDAPT (DIN 02466236) under ATC L01EX10 MIDOSTAURIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 8, 2017	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as REDDY-NILOTINIB (DIN 02556634) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 24, 2025	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as REDDY-NILOTINIB (DIN 02556642) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 24, 2025	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as APO-NILOTINIB (DIN 02550903) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 13, 2025	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as APO-NILOTINIB (DIN 02550881) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 13, 2025	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as TASIGNA (DIN 02481715) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 4, 2023	May 17, 2019	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as TASIGNA (DIN 02368250) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 15, 2011	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as TASIGNA (DIN 02315874) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2008	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as PMS-NILOTINIB (DIN 02565005) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as PMS-NILOTINIB (DIN 02564947) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Nilotinib	CA Health Canada	—	Marketed in Canada as REDDY-NILOTINIB (DIN 02556626) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Ponatinib	CA Health Canada	—	Marketed in Canada as ICLUSIG (DIN 02437341) under ATC L01EA05 PONATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Aug 8, 2022	Jan 7, 2016	health-canada-dpd
Ponatinib	CA Health Canada	—	Marketed in Canada as ICLUSIG (DIN 02437333) under ATC L01EA05 PONATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 21, 2015	health-canada-dpd
Regorafenib	CA Health Canada	—	Marketed in Canada as STIVARGA (DIN 02403390) under ATC L01EX05 REGORAFENIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 2, 2013	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO (DIN 02530147) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 3, 2023	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO (DIN 02530139) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 3, 2023	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO GRANULES (DIN 02569744) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO GRANULES (DIN 02569736) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sorafenib	CA Health Canada	—	Marketed in Canada as NEXAVAR (DIN 02284227) under ATC L01EX02 SORAFENIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2006	health-canada-dpd
Sorafenib	CA Health Canada	—	Marketed in Canada as APO-SORAFENIB (DIN 02490641) under ATC L01EX02 SORAFENIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02539284) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02552892) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02552906) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532190) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 18, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526204) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526220) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526212) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532204) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 21, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532220) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 21, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SANDOZ SUNITINIB (DIN 02532867) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 24, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SANDOZ SUNITINIB (DIN 02532840) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 24, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SANDOZ SUNITINIB (DIN 02532883) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 24, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TARO-SUNITINIB (DIN 02524058) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 17, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TARO-SUNITINIB (DIN 02524066) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 20, 2022	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TARO-SUNITINIB (DIN 02524082) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 20, 2022	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SUTENT (DIN 02280795) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 22, 2006	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SUTENT (DIN 02280817) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 22, 2006	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SUTENT (DIN 02280809) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 22, 2006	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532212) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TARO-SUNITINIB (DIN 02524074) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SANDOZ SUNITINIB (DIN 02532875) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as EUGIA-SUNITINIB (DIN 02548062) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SUTENT (DIN 02328607) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 31, 2025	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as EUGIA-SUNITINIB (DIN 02548038) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as EUGIA-SUNITINIB (DIN 02548046) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as EUGIA-SUNITINIB (DIN 02548054) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd